Plymouth, Scaffolders

Plymouth Scaffolder's Asbestos Death Ruled Industrial Disease

Published on 08/14/2026 at 17:17 | Redaktion boerse-global.de

An inquest has ruled that a former Plymouth scaffolder died from an aggressive cancer caused by asbestos exposure at a Royal Navy dockyard. Denis Tapp, 72, passed away in March 2025 from pleural…

An inquest has ruled that a former Plymouth scaffolder died from an aggressive cancer caused by asbestos exposure at a Royal Navy dockyard. Denis Tapp, 72, passed away in March 2025 from pleural…
Plymouth Scaffolder's Asbestos Death Ruled Industrial Disease Illustration mit AI erstellt übermittelt durch boerse-global.de

An inquest has ruled that a former Plymouth scaffolder died from an aggressive cancer caused by asbestos exposure at a Royal Navy dockyard. Denis Tapp, 72, passed away in March 2025 from pleural mesothelioma, a disease closely linked to inhaling asbestos fibres. The case highlights the long-tail health risks facing UK workers who handled the material decades ago, and the ongoing legal and regulatory fallout for employers.

Mr Tapp was exposed to asbestos during his time at Devonport dockyard between 1978 and 1984. The inquest officially recorded his death as industrial disease. A civil claim linked to the exposure had been started before his death but remained unresolved.

Advertisement

Cases like this are a stark reminder that the consequences of inadequate safety documentation can surface decades later. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace risks properly from the start. Download the free Risk Assessment Toolkit

Legacy of Industrial Exposure

The case adds to a growing list of developments involving workers who developed mesothelioma years after workplace exposure. In a separate matter, legal representatives for John Yates, a man from Warrington, are seeking information from former colleagues at Leyland Vehicles Ltd, Leyland DAF, and Albion Automotive. Mr Yates was diagnosed with mesothelioma in April 2026 after working at those sites between 1987 and 2005.

Regulators continue to penalise historical safety failures. Lima Construction was recently fined £50,000 over the 2022 death of Antonio Rodrigues. The 55-year-old worker died after falling three metres through an unglazed window on a scaffolding rig in London. The Health and Safety Executive (HSE) found the firm failed to provide protective boarding and neglected required weekly inspections.

Oversight and Remediation Efforts

Authorities are stepping up inspections of public and residential buildings for asbestos mismanagement. In the United Kingdom, Cumberland Council received an improvement notice from the HSE regarding Whitehaven Civic Hall. Inspections carried out between December 2025 and February 2026 revealed the absence of a required asbestos management plan. The council has since appointed an external auditor and a designated officer to oversee compliance.

Community spaces are also feeling the effects of long-term remediation. Chalford Valley Playing Field in Stroud is set to reopen on August 28 after a year-long closure. The site was shut after chrysotile, crocidolite, and amosite asbestos were found beneath the surface. Officials have now classified the risk as Category 4, the lowest possible rating.

Advertisement

When hazardous substances are involved, the legal duty to assess and control risks falls squarely on employers. A free COSHH toolkit with 43 customisable templates and checklists helps you meet your obligations under current regulations. Download the free COSHH Toolkit

Overseas, Illinois' Attorney General obtained an injunction against Ryze Properties and Outlook Design & Construction for the improper removal of asbestos-containing materials at a 15-unit residential building in Chicago Heights. The court order requires the firms to hire licensed professionals and follow an approved abatement plan.

Medical Research Developments

As industrial disease cases continue to emerge, UK clinical trials have reported progress in treating mesothelioma. A Phase 1 study of a new drug, RSO-021 (Thiostrepton), found the treatment inhibits the PRX3 protein. The drug successfully controlled disease progression in 67% of mesothelioma patients.

Researchers noted that participants saw a median progression-free survival period of 4.2 months. The trial results suggested a survival benefit for 15 patients involved in the early stage of the drug's development, offering a potential new avenue for those diagnosed with the condition.

Disclaimer...

en | boerse | 69950180 |